Compare HOVR & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOVR | IFRX |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | Canada | Germany |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.1M | 86.0M |
| IPO Year | N/A | 2017 |
| Metric | HOVR | IFRX |
|---|---|---|
| Price | $1.75 | $1.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $6.50 | ★ $8.50 |
| AVG Volume (30 Days) | 1.1M | ★ 7.7M |
| Earning Date | 01-13-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $73,729.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $55.08 | $1,075.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.35 | $0.71 |
| 52 Week High | $4.18 | $2.82 |
| Indicator | HOVR | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.47 | 42.21 |
| Support Level | $1.16 | $0.92 |
| Resistance Level | $1.69 | $1.28 |
| Average True Range (ATR) | 0.17 | 0.11 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 77.22 | 30.42 |
New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and building a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities, and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, floods, and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.